JP2024528705A5 - - Google Patents
Info
- Publication number
- JP2024528705A5 JP2024528705A5 JP2024503903A JP2024503903A JP2024528705A5 JP 2024528705 A5 JP2024528705 A5 JP 2024528705A5 JP 2024503903 A JP2024503903 A JP 2024503903A JP 2024503903 A JP2024503903 A JP 2024503903A JP 2024528705 A5 JP2024528705 A5 JP 2024528705A5
- Authority
- JP
- Japan
- Prior art keywords
- present
- gpa
- acid
- cancer
- cancer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163223926P | 2021-07-20 | 2021-07-20 | |
| US63/223,926 | 2021-07-20 | ||
| PCT/US2022/073884 WO2023004308A1 (en) | 2021-07-20 | 2022-07-19 | Compositions and methods for inhibiting creatine transport as a treatment for cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528705A JP2024528705A (ja) | 2024-07-30 |
| JP2024528705A5 true JP2024528705A5 (enExample) | 2025-07-25 |
Family
ID=84979767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503903A Pending JP2024528705A (ja) | 2021-07-20 | 2022-07-19 | がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240180912A1 (enExample) |
| EP (1) | EP4373582A4 (enExample) |
| JP (1) | JP2024528705A (enExample) |
| AU (1) | AU2022316200A1 (enExample) |
| CA (1) | CA3225305A1 (enExample) |
| WO (1) | WO2023004308A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250085767A (ko) | 2022-09-29 | 2025-06-12 | 광조우 조요 파마테크 컴퍼니 리미티드 | 거대고리 유도체 및 이의 적용 |
| CN116602948B (zh) * | 2023-06-06 | 2024-12-06 | 湖南岳靶生物医药有限公司 | 一种可用于降低膀胱癌细胞耐药性的化合物、组合物及其应用 |
| WO2025114580A1 (en) * | 2023-11-30 | 2025-06-05 | National And Kapodistrian University Of Athens | N-aminoguanidine derivatives with anticancer activity |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014071067A2 (en) * | 2012-10-31 | 2014-05-08 | The Rockefeller University | Treatment and diagnosis of colon cancer |
| US20180002702A1 (en) * | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US12582667B2 (en) * | 2019-09-27 | 2026-03-24 | The Rockefeller University | Compositions and methods to treat metastatic gastrointestinal cancer |
| KR20220086628A (ko) * | 2019-10-22 | 2022-06-23 | 루핀 리미티드 | Prmt5 저해제의 약학적 조합물 |
| EP4072561A4 (en) * | 2019-12-11 | 2023-11-29 | Inspirna, Inc. | CANCER TREATMENT METHODS |
-
2022
- 2022-07-19 JP JP2024503903A patent/JP2024528705A/ja active Pending
- 2022-07-19 AU AU2022316200A patent/AU2022316200A1/en active Pending
- 2022-07-19 CA CA3225305A patent/CA3225305A1/en active Pending
- 2022-07-19 EP EP22846790.8A patent/EP4373582A4/en active Pending
- 2022-07-19 WO PCT/US2022/073884 patent/WO2023004308A1/en not_active Ceased
-
2024
- 2024-01-19 US US18/417,491 patent/US20240180912A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024528705A5 (enExample) | ||
| Yamada et al. | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial | |
| LoConte et al. | A multicenter phase 1 study of γ-secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors | |
| AU2022291015A1 (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| US20110053879A1 (en) | Picoplatin and amrubicin to treat lung cancer | |
| US12102613B2 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| JP2019532051A5 (enExample) | ||
| JP2023523323A5 (enExample) | ||
| CN113750238A (zh) | 包含瓦尼替尼及抗癌剂之组合疗法 | |
| JP2024527109A5 (enExample) | ||
| CN110198716A (zh) | 癌症治疗 | |
| US10512648B2 (en) | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake | |
| CN118201616A (zh) | 用于癌症的wee1抑制剂 | |
| WO2011092338A1 (en) | Combined treatment of pancreatic cancer with gemcitabine and masitinib | |
| Planchard et al. | A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS-or BRAF-mutant non-small cell lung cancer | |
| TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| JP2005513167A (ja) | エポシロン誘導体と代謝拮抗剤からなる組合せ | |
| TW201907916A (zh) | 基於癌細胞之代謝特異性之新穎抗惡性腫瘤劑 | |
| WO2021018310A1 (zh) | 用于治疗非小细胞肺癌的氨基吡啶衍生物 | |
| Sawicka et al. | Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question? | |
| CN111867591A (zh) | 治疗胆道癌的方法和组合疗法 | |
| CN102883720A (zh) | 治疗胰腺癌的方法 | |
| Takiguchi et al. | Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study | |
| CN115135326A (zh) | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 | |
| CN120154618B (zh) | 格索雷塞用于治疗肺癌的用途或其药物组合物 |